865 POSTER Zoledronic acid reduces bone loss in men with prostate cancer undergoing androgen blockade with luteinizing hormone-releasing hormone analogues

首页> 外文期刊>European Journal of Cancer Supplements >865 POSTER Zoledronic acid reduces bone loss in men with prostate cancer undergoing androgen blockade with luteinizing hormone-releasing hormone analogues

【24h】

865 POSTER Zoledronic acid reduces bone loss in men with prostate cancer undergoing androgen blockade with luteinizing hormone-releasing hormone analogues

机译：865 POSTER唑来膦酸通过黄体生成激素释放激素类似物减少雄激素阻断的前列腺癌男性的骨质流失

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2005年第2期|共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Combination of somatostatin analogues and dexamethasone (antisurvival-factor concept) with luteinizing hormone-releasing hormone in androgen ablation-refractory prostate cancer with bone metastasis [J] . Michael Koutsilieris, Theodore Dimopoulos, Constantine Milathianakist, BJU international . 2007,第2期

机译：生长激素抑制素类似物和地塞米松（抗存活因子概念）与促黄体激素释放难治性前列腺癌骨转移的促黄体激素释放激素的组合
2. Frequency of zoledronic acid to prevent further bone loss in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer [J] . Vivek K. Wadhwa Robin Weston Nigel J. Parr BJU International . 2010,第8期

机译：唑来膦酸预防接受雄激素剥夺治疗的骨质疏松症患者进一步骨丢失的频率
3. Frequency of zoledronic acid to prevent further bone loss in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer [J] . Vivek K. Wadhwa, Robin Weston, Nigel J. Parr BJU international . 2010,第8期

机译：唑来膦酸预防接受雄激素剥夺治疗的骨质疏松症患者进一步骨丢失的频率
4. Synthesis and structural studies of new analogues of the decapeptide Luteinizing Hormone-Releasing Hormone (LHRH) [C] . Aikaterini A.Zompra, Dimitris Vachliotis, Georgios A.Spyroulias, European Peptide Symposium . 2002

机译：疏皮肽丁骨释放激素（LHRH）新型类似物的合成与结构研究
5. Changes in bone mineral density in men with prostate cancer during treatment with luteinizing hormone-releasing hormone (LHRH) agonist monotherapy. [D] . Conde, Francisco Alcasid, II. 2003

机译：黄体激素释放激素（LHRH）激动剂单药治疗期间前列腺癌男性的骨矿物质密度变化。
6. Zoledronic acid prevents decreases in bone mineral density in patients with prostate cancer undergoing combined androgen blockade [O] . Satoshi Nishizawa, Takeshi Inagaki, Akinori Iba, -1

机译：唑来膦酸可预防合并雄激素阻断的前列腺癌患者的骨矿物质密度降低
7. Zoledronic acid prevents decreases in bone mineral density in patients with prostate cancer undergoing combined androgen blockade [O] . Satoshi Nishizawa, Takeshi Inagaki, Akinori Iba, 2014

机译：唑来膦酸可预防合并雄激素阻断的前列腺癌患者的骨矿物质密度降低

865 POSTER Zoledronic acid reduces bone loss in men with prostate cancer undergoing androgen blockade with luteinizing hormone-releasing hormone analogues

著录项

相似文献

相关主题

期刊订阅